Introduction {#s1}
============

Epidermal growth factor receptor (EGFR) mutation status divides non-small cell lung cancer (NSCLC) into two genetic subsets, NSCLC with positive EGFR mutation and NSCLC with wild-type EGFR. For the former subset, EGFR tyrosine kinase inhibitors (EGFR-TKIs) provide better efficacy and longer survival than conventional cytotoxic chemotherapy. Thus, exclusively for these selected patients, EGFR-TKIs are prioritized over conventional chemotherapy. However, these drugs are not always effective for them. Overall response rate ranged 60-80%. Many patients experienced tumor progression 9 - 13 months after initiation of EGFR-TKIs \[[@R01]-[@R06]\].

Patient's systemic inflammatory response (SIR) plays an adverse role in development and prognosis of cancers \[[@R07]-[@R9]\]. Neutrophils, lymphocytes and monocytes are important for the cancer-induced SIR \[[@R10], [@R11]\]. These three types of circulating cells represent the patients' SIR. Their peripheral absolute counts can predict prognoses of various malignancies, including NSCLC. According to a Japanese analysis of 388 chemo-naive NSCLC with stage IIIB or IV, pretreatment elevated neutrophil count was significantly associated with shorter overall survival (OS) and progression-free survival (PFS). However, this study failed to show any association between prognosis and lymphocyte or monocyte count \[[@R12]\]. On the other hand, another Japanese multivariate analysis of 237 node-negative NCSLC demonstrated that a preoperative peripheral lymphocyte count was an independent prognostic factor for OS rate, but the neutrophil count was not \[[@R13]\]. A Chinese multivariate analysis of 142 patients with NSCLC who had underwent lobectomy, lymph node dissection and adjuvant chemotherapy also detected preoperative lymphocyte count, but not neutrophil count, as an independent prognostic factor of disease-free survival \[[@R14]\]. These two studies considered that peripheral lymphocyte count was associated with vascular or lymphatic invasion \[[@R13], [@R14]\]. Regarding peripheral monocyte count, in a Chinese analysis of 370 patients who had received platinum-based doublet for previously untreated metastatic NSCLC, monocyte count was an independent prognostic factor for PFS and OS \[[@R15]\].

Recently, there has been increasing evidences of the prognostic value of combined scoring systems based on the SIR. Especially, neutrophil-to-lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR) are easily calculated from leukocyte count and differentiation. Elevated NLR \[[@R16]-[@R18]\] and decreased LMR \[[@R15], [@R19]\] have been demonstrated to be associated with poor prognosis in various cancers, including advanced NSCLC. However, little has been known about these two ratios for a specific genetic subset of EGFR mutant NSCLC.

In this study, we evaluate the prognostic value of NLR and LMR in patients with EGFR mutant NSCLC.

Methods {#s2}
=======

This study was retrospective and single institutional. We collected the following patients: 1) patients who started EGFR-TKIs monotherapy between October 2007 and February 2017, 2) histologically or cytologically proven NSCLC, and positive EGFR mutation status confirmed by the peptide nucleic acid-locked nucleic acid PCR clamp method by LSI Medience Cooperation (Tokyo, Japan) \[[@R20]\], 3) c-stage IIIA-B, IV or post-surgical recurrence, based on the 7th TNM classification of lung cancer by the Union for International Cancer Control (UICC) \[[@R21]\], 4) patients who received blood test within 1 week before the initiation of EGFR-TKIs. In Japan, gefitinib, erlotinib and afatinib were approved for NSCLC in July 2002, October 2007 and January 2014, respectively. EGFR mutation tests became covered by insurance in June 2007. The definitions of overall response rate (RR), disease control rate (DCR), PFS and OS in this study followed those of our previous studies \[[@R22], [@R23]\]. When RR, DCR and PFS were calculated, sequential change from a TKI to another TKI due to adverse effects was arbitrarily defined as one regimen treatment in this study. When we calculated creatinine clearance (Ccr) by means of Cockcroft-Gault equation, we added 0.2 mg/dL on serum creatinine values determined by the enzymatic method \[[@R24]\]. Peripheral venous blood (approximately 2 mL) was collected into a sterile ethylene-diamine-tetra-acetic acid (EDTA) tube. Hematological parameters were analyzed using hematology analyzers (Sysmex XE-2100 until 2012, and thereafter Sysmex XE-5000; Sysmex, Kobe, Japan). NLR and LMR were obtained by dividing pretreatment venous absolute circulating neutrophil count by lymphocyte count, and venous absolute circulating lymphocyte count by monocyte count, respectively. The data cut-off was September 1, 2017. The Osaka Police Hospital Ethics Committee approved this study (number 685), and waived the requirement for informed consent because de-identified data were retrospectively collected.

We described the continuous, categorical and survival variables as the mean ± standard deviation (SD), frequency, median (95% confidential intervals (CIs)), respectively. We used Fisher's exact and Mann-Whitney tests for comparison of the relative frequencies and continuous variables that were not normally distributed, respectively. Using receiver operating characteristic (ROC) curve and Youden index, we selected the optimal cut-off values of NLR and LMR, and then divided our patients into two groups. We arbitrary defined complete and partial responses of EGFR-TKIs as the outcome variables of ROC analysis. The results of ROC analyses were expressed as sensitivity, specificity, area under the curve (AUC) with 95% CI. We used Kaplan-Meier method to evaluate PFS and OS, and compared two groups by log-rank test.

To investigate independent prognostic factors, we used Cox proportional hazard analyses. After the univariate analysis, only variables with P-value \< 0.1 were used in the multivariate analysis. The results were described as hazard ratios (HR) and 95% CI. P-value \< 0.05 was defined as statistically significant. All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria) \[[@R25]\].

Results {#s3}
=======

We collected 152 patients for this study. At the time of data-cut off, 85 patients were dead, 39 still alive and 28 lost to follow-up. As for the first TKI treatment, 15 patients still continued TKI, while the other 137 discontinued TKI because of PD in 84, adverse effects in 20, deteriorated comorbidity or general condition in 17, change regimens from EGFR-TKI to cytotoxic drugs before PD in 5, patients' refusal in 3, transfer to other hospitals in 6 and unidentified death in 2. Eleven patients changed TKIs mainly due to adverse effects. As the optimal cut-off points of NLR and LMR, ROC curves defined 2.11 (sensitivity 0.75, specificity 0.42, AUC 0.54, 95% CI 0.44 - 0.64) and 5.09 (sensitivity 0.83, specificity 0.39, AUC 0.60, 95% CI 0.51 - 0.69), respectively.

High NLR group (NLR ≥ 2.11) included more patients with bone metastases (45% vs. 20%, P \< 0.01) and severe Eastern Cooperative Oncology Group performance status (ECOG PS) (P \< 0.01) than low NLR group (NLR \< 2.11). High LMR group (LMR ≥ 5.09) was characteristics of more female (74% vs. 57%, P = 0.047), less frequent bone metastases (21% vs. 43%, P = 0.01), better PS (P \< 0.01) than low LMR group (LMR \< 5.09) ([Table 1](#T1){ref-type="table"}). Patients with low NLR were more likely to receive further line chemotherapy (76% vs. 58%, P = 0.03). RR were significantly higher in high LMR group than in low LMR group (76.6% vs. 54.3%, P = 0.01). DCRs were significantly higher in low NLR (92.6% vs. 73.5%, P \< 0.01) and high LMR (93.6% vs. 74.3%, P \< 0.01) groups than in high NLR and low LMR groups ([Table 2](#T2){ref-type="table"}). OS of low NLR (OS, 38.6 vs. 24.1 months in median, P \< 0.01) and high LMR (OS, 39.4 vs. 26.4 months, P \< 0.01) groups were significantly longer than those of high NLR and low LMR groups ([Fig. 1](#F1){ref-type="fig"}). However, PFS of low NLR (PFS, 15.9 vs. 10.1 months in median, P = 0.04) group was significantly longer than those of high NLR group, while there was no statistically significant difference in PFS according to LMR ([Fig. 2](#F2){ref-type="fig"}).

###### Comparisons of Backgrounds and Laboratory Data Between Two Groups Divided According to Neutrophil-to-Lymphocyte and Lymphocyte-to-Monocyte Ratios

  Groups                          ALL             NLR             LMR                                                          
  ------------------------------- --------------- --------------- --------------- ------------ --------------- --------------- ------------
  N                               152             54              98                           105             47              
  Backgrounds                                                                                                                  
    Age (years, mean ± SD)        70.3 ± 10.3     70.5 ± 8.6      70.2 ± 11.1     0.66^a^      70.4 ± 10.7     70.1 ± 9.4      0.69^a^
    Sex (N, male/female)          57/95           15/39           42/56           0.08^b^      45/60           12/35           0.047^b^
    Histology (N, Ad/others)      148/4           54/0            94/4            0.30^b^      101/4           47/0            0.31^b^
    Stage (N, IIIA/IIIB/IV/Rec)   10/3/102/37     4/2/30/18       6/1/72/19       0.10^b^      6/1/74/24       4/2/28/13       0.32^b^
    Distant met (N)               132             46              86              0.44^b^      95              39              0.28^b^
      Brain met (N)               32              13              19              0.54^b^      21              11              0.67^b^
      Liver met (N)               14              3               11              0.38^b^      10              4               1.00^b^
      Bone met (N)                55              11              44              \< 0.01^b^   45              10              0.01^b^
    ECOG PS (N, 0 - 1/2/3/4)      111/32/7/2      49/5/0/0        62/27/7/2       \< 0.01^b^   68/28/7/2       43/4/0/0        \< 0.01^b^
    BMI (mean ± SD)               21.8 ± 4.1      22.0 ± 3.3      21.6 ± 4.5      0.13^a^      21.7 ± 4.4      22.0 ± 3.4      0.30^a^
    EGFR mt (N)^c^                                                                                                             
      Ex 19del                    74              27              47                           50              24              
      Ex 21 point mt              74              25              49                           53              21              
      Minor mt                    6               3               3                            3               3               
      Ex19 del vs. other          74/78           27/27           47/51           0.87^b^      50/55           24/23           0.73^b^
  Laboratory data                                                                                                              
    Neut (cells/µL)               4,183 ± 1,956   3,075 ± 1,095   4,793 ± 2,060   \< 0.01^a^   4,606 ± 2,093   3,237 ± 1,155   \< 0.01^a^
    Lymph (cells/µL)              1,496 ± 605     1,962 ± 554     1,239 ± 463     \< 0.01^a^   1,338 ± 507     1,850 ± 659     \< 0.01^a^
    Mono (cells/µL)               411 ± 177       349 ± 123       446 ± 193       \< 0.01^a^   468 ± 175       286 ± 101       \< 0.01^a^

^a^Mann-Whitney test. ^b^Fisher's extract test. ^c^Double mutations. Exon 19del + Exon 21 L858R and Exon 21 L858R + Exon 18 G719S in each one case. Ad: adenocarcinoma; BMI: body mass index; del: deletion; CI: confidence interval; ECOG PS: Eastern Cooperative Oncology Group performance status; LMR: lymphocyte-to-monocyte ratio; Lymph: lymphocyte; met: metastasis; Mono: monocyte; mt: mutation; Neut: neutrophil; NLR: neutrophil-to-lymphocyte ratio; Rec: post-surgical recurrence; SD: standard deviation.

###### Treatment and Outcomes

  Group                                All                  NLR                  LMR                                                                      
  ------------------------------------ -------------------- -------------------- -------------------- --------- -------------------- -------------------- ---------
  N                                    152                  54                   98                             105                  47                   
  TKI choice (N, Gef/Erl/Afa)          107/36/9             43/10/1              64/26/8              0.12      72/27/6              35/9/3               0.68
  TKI line (N, first/second/≥ third)   104/38/11            37/14/4              67/24/7              1.00      71/27/7              33/11/3              0.96
  Pre TKI treatment (N)                49                   18                   31                   0.86      34                   10                   0.18
    Platinum-based                     39                   14                   25                   1.00      30                   7                    0.10
    Curative-intent TRT                8                    3                    5                    1.00      6                    2                    1.00
  Post TKI treatment (N)               98                   41                   57                   0.03      64                   34                   0.20
    Cytotoxic drugs                    62                   26                   36                   0.23      40                   22                   0.37
      Platinum-based                   27                   10                   17                   1.00      18                   13                   0.19
    Osimertinib                        14                   5                    9                    1.00      9                    5                    0.76
    Re-challenge of TKI                62                   27                   35                   0.12      42                   22                   0.48
  Palliative radiotherapy (N)          57                   18                   39                   0.49      38                   19                   0.72
  TKI Response (N)                                                                                                                                        
    Complete response                  5                    3                    2                              2                    3                    
    Partial response                   88                   36                   52                             55                   33                   
    Stable disease                     29                   11                   18                             21                   8                    
    Progressive disease                19                   2                    17                             18                   1                    
    Not evaluated                      11                   2                    9                              9                    2                    
  RR (%) (95% CI)                      61.2 (53.0 - 69.0)   72.2 (58.4 - 83.5)   55.1 (44.7 - 65.2)   0.055     54.3 (44.3 - 64.0)   76.6 (62.0 - 87.7)   0.01
  DCR (%) (95% CI)                     80.3 (73.0 - 86.3)   92.6 (82.1- 97.9)    73.5 (63.6 - 81.9)   \< 0.01   74.3 (64.8 - 82.3)   93.6 (82.5 - 98.7)   \< 0.01

^a^Fisher's extract test. Afa: afatinib; CI: confidence interval; DCR: disease control rate; Erl: erlotinib; Gef: gefitinib; LMR: lymphocyte-to-monocyte ratio; NLR: neutrophil-to-lymphocyte ratio; RR: response rate; TKI: tyrosine kinase inhibitor; TRT: thoracic radiotherapy.
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![Kaplan-Meier curves of progression-free survival (PFS). (a) Neutrophil-to-lymphocyte ratio (NLR). (b) Lymphocyte-to-monocyte ratio (LMR).](wjon-08-180-g002){#F2}

Univariate analyses detected ECOG PS 0 - 1, higher Ccr, higher sodium concentration, lower lactate dehydrogenase (LDH), lower C-reactive protein (CRP), lower NLR and higher LMR as prognostic factors for longer OS; no distant metastasis, ECOG PS 0 - 1, body mass index (BMI) ≥ 18.5, EGFR-TKI introduction in first-line setting, treatment with erlotinib or afatinib, higher Ccr, higher sodium concentration, lower LDH, lower CRP, lower NLR and higher LMR as predictive factors for longer PFS ([Table 3](#T3){ref-type="table"}). The subsequent multivariate analyses found lower NLR (HR 1.07, 95%CI: 1.01 - 1.14; P = 0.03) as an independent prognostic factor for longer OS, in addition to ECOG PS 0 - 1, first-line introduction of EGFR-TKI, higher sodium concentration and lower LDH. However, LMR was not detected as a significant prognostic factor for OS ([Table 4](#T4){ref-type="table"}). Neither NLR nor LMR was selected as a significant prognostic factor for PFS ([Table 5](#T5){ref-type="table"}).

###### Univariate Cox Hazard Analyses of Factors Associated With Overall Survival and Progression-Free Survival

                                              OS     PFS                                           
  ------------------------------------------- ------ -------------- --------- ------ ------------- ---------
  Age (years \< 75 vs. ≥ 75)                  1.18   0.75 - 1.85    0.48      0.97   0.67 - 1.41   0.88
  Sex (female vs. male)                       1.33   0.86 - 2.07    0.19      1.17   0.81 - 1.68   0.41
  Distant metastasis (no vs. yes)             2.08   0.99 - 4.38    0.054     2.10   1.12 - 3.93   0.02
  ECOG PS (0 - 1 vs. 2 - 4)                   4.08   2.56 - 6.50    \< 0.01   1.98   1.33 - 2.93   \< 0.01
  BMI (≥ 18.5 vs. \< 18.5)                    1.58   0.95 - 2.64    0.08      1.60   1.04 - 2.47   0.03
  EGFR mutation (exon 19 del vs. others)      1.27   0.82 - 1.95    0.29      1.14   0.79 - 1.63   0.49
  EGFR-TKI line (first vs. second or later)   1.46   0.94 - 2.26    0.09      1.47   1.01 - 2.15   0.04
  EGFR-TKI (Gef vs. Erl or Afa)               0.84   0.50 - 1.41    0.51      0.61   0.40 - 0.92   0.02
  Hemoglobin (g/dL)                           0.89   0.77 - 1.02    0.09      0.94   0.85 - 1.05   0.29
  Ccr (mL/min) (/10)                          0.86   0.74 - 0.998   0.047     0.88   0.78 - 0.99   0.04
  Sodium (mEq/L) (/10)                        0.19   0.10 - 0.39    \< 0.01   0.34   0.19 - 0.62   \< 0.01
  LDH (IU/L) (/100)                           1.36   1.19 - 1.54    \< 0.01   1.24   1.11 - 1.39   \< 0.01
  CRP (mg/dL)                                 1.17   1.08 - 1.27    \< 0.01   1.19   1.10 - 1.29   \< 0.01
  NLR                                         1.12   1.07 - 1.18    \< 0.01   1.08   1.03 - 1.13   \< 0.01
  LMR                                         0.78   0.69 - 0.89    \< 0.01   0.89   0.81 - 0.98   0.02

Afa: afatinib; BMI: body mass index; Ccr: creatinine clearance; CI: confidence interval; CRP: C-reactive protein; del: deletion; ECOG PS: Eastern Cooperative Oncology Group performance status; EGFR-TKI: epidermal growth factor receptor- tyrosine kinase inhibitor; Erl: erlotinib; Gef: gefinitib; HR: hazard ratio; LDH: lactate dehydrogenase; LMR: lymphocyte-to-monocyte ratio; NLR: neutrophil-to-lymphocyte ratio; OS: overall survival; PFS: progression-free survival.

###### Multivariate Cox Hazard Analyses of Factors Associated With Overall Survival

                                              NLR     LMR                                          
  ------------------------------------------- ------- ------------- --------- ------ ------------- ---------
  Distant metastasis (no vs. yes)             1.59    0.73 - 3.50   0.25      1.44   0.64 - 3.24   0.38
  ECOG PS (0 - 1 vs. 2 - 4)                   3.46    2.03 - 5.89   \< 0.01   3.41   1.99 - 5.82   \< 0.01
  BMI (≥ 18.5 vs. \< 18.5)                    1.62    0.89 - 2.93   0.12      1.58   0.87 - 2.87   0.14
  EGFR-TKI line (first vs. second or later)   1.71.   1.07 - 2.73   0.02      1.72   1.08 - 2.74   0.02
  Hemoglobin (g/dL)                           1.14    0.97 - 1.34   0.11      1.15   0.98 - 1.36   0.08
  Ccr (mL/min) (/10)                          0.86    0.73 - 1.02   0.08      0.86   0.73 - 1.01   0.07
  Sodium (mEq/L) (/10)                        0.30    0.13 - 0.71   \< 0.01   0.27   0.11 - 0.64   \< 0.01
  LDH (IU/L) (/100)                           1.24    1.05 - 1.48   0.01      1.27   1.07 - 1.50   \< 0.01
  CRP (mg/dL)                                 1.01    0.90 - 1.14   0.82      0.98   0.86 - 1.11   0.74
  NLR                                         1.07    1.01 - 1.14   0.03      \-     \-            \-
  LMR                                         \-      \-            \-        0.88   0.76 - 1.01   0.07

BMI: body mass index; Ccr: creatinine clearance: CI: confidence interval; CRP: C-reactive protein; ECOG PS: Eastern Cooperative Oncology Group performance status; EGFR-TKI: epidermal growth factor receptor-tyrosine kinase inhibitors; HR: hazard ratio; LDH: lactate dehydrogenase; LMR: lymphocyte-to-monocyte ratio; NLR: neutrophil-to-lymphocyte ratio.

###### Multivariate Cox Hazard Analyses of Factors Associated With Progression-Free Survival

                                              NLR    LMR                                        
  ------------------------------------------- ------ ------------- ------- ------ ------------- -------
  Distant metastasis (no vs. yes)             1.69   0.87 - 3.27   0.12    1.77   0.92 - 3.42   0.09
  ECOG PS (0 - 1 vs. 2 - 4)                   1.55   0.97 - 2.47   0.07    1.63   1.01 - 2.61   0.04
  BMI (≥ 18.5 vs. \< 18.5)                    1.53   0.94 - 2.47   0.09    1.57   0.96 - 2.55   0.07
  EGFR-TKI line (first vs. second or later)   1.47   0.99 - 2.19   0.058   1.49   1.00 - 2.23   0.049
  EGFR-TKI (Gef vs. Erl or Afa)               0.63   0.40 - 0.99   0.046   0.64   0.41 - 1.01   0.06
  Ccr (mL/min) (/10)                          0.94   0.82 - 1.08   0.37    0.94   0.82 - 1.07   0.36
  Sodium (mEq/L) (/10)                        0.60   0.30 - 1.20   0.15    0.60   0.30 - 1.21   0.16
  LDH (IU/L) (/100)                           1.11   0.97 - 1.27   0.15    1.12   0.98 - 1.29   0.10
  CRP (mg/dL)                                 1.10   0.99 - 1.22   0.08    1.10   0.99 - 1.23   0.07
  NLR                                         1.03   0.97 - 1.10   0.29    \-     \-            \-
  LMR                                         \-     \-            \-      1.00   0.90 - 1.12   0.99

Afa: afatinib; ALP: alkaline phosphatase; BMI: body mass index; Ccr: creatinine clearance; CI: confidence interval; CRP: C-reactive protein; ECOG PS: Eastern Cooperative Oncology Group performance status; EGFR-TKI: epidermal growth factor receptor-tyrosine kinase inhibitors; Erl: erlotinib; Gef: gefitinib; HR: hazard ratio; LDH: lactate dehydrogenase; LMR: lymphocyte-to-monocyte ratio; NLR: neutrophil-to-lymphocyte ratio.

Discussion {#s4}
==========

This study was a comprehensive evaluation of two biomarkers and prognosis in patients with EGFR mutant NSCLC treated with EGFR-TKIs. To our knowledge, there were only four studies and one study that had investigated association of NLR \[[@R26]-[@R29]\] and LMR \[[@R30]\] with prognosis, respectively ([Table 6](#T6){ref-type="table"}).

###### Review of Previous Studies of Multivariate Analyses for Prediction of Survival Outcomes in Patients With EGFR Mutant NSCLC

  Author (year)                     Country     N     Treatment                              Variable   Multivariate analyses                                                              
  --------------------------------- ----------- ----- -------------------------------------- ---------- ----------------------- ----------------------- ---------- ----------------------- ----------
  Lin et al \[[@R27]\] (2014)       China       81    Gef (30%) Erl (70%) All first-line     NLR        3.5                     3.29 (1.62 - 6.71)      \< 0.001   3.89 (1.98 - 7.68)      \< 0.001
  Chen et al \[[@R30]\] (2015)      Taiwan      253   All first-line                         LMR        3.29                    2.36 (1.66 - 3.35)      \< 0.001   1.71 (1.14 - 2.56)      0.009
  Sim et al \[[@R29]\] (2016)       Korea       85    All first-line                         NLR        3                       NA                      NA         1.239 (0.693 - 2.215)   0.469
  Meriggi et al \[[@R28]\] (2017)   Italy       63    Gef (71%) Erl (29%)                    NLR        3.5                     2.699 (1.187 - 6.137)   0.018      2.275 (1.257 - 4.116)   0.007
  Ding et al \[[@R26]\] (2017)      Australia   85    First-line (85%)                       NLR        5                       0.43 (0.19 - 0.94)      0.04       0.40 (0.18 - 0.87)      0.02
  Ours                              Japan       152   Gef (70%) Erl (24%) First-line (68%)   NLR        \-                      1.07 (1.01 - 1.14)      0.03       1.03 (0.97 - 1.10)      0.29
                                                                                             LMR        \-                      0.88 (0.76 - 1.01)      0.07       1.00 (0.90 - 1.12)      0.99

CI: confidence interval; Erl: erlotinib; Gef: gefitinib; HR: hazard ratio; NA: not assessed; LMR: lymphocyte-to-monocyte ratio; NLR: neutrophil-to-lymphocyte ratio; OS: overall survival; PFS: progression free survival.

NLR is an independent prognostic factor for OS of those selected population. Our survival comparisons and multivariate analyses demonstrated that higher NLR was associated with poorer OS, and were consistent with previous three studies \[[@R26]-[@R28]\]. On the other hand, despite of significantly longer OS in patients with LMR ≥ 5.09, our multivariate analysis failed to detect LMR as a significant prognostic factor for OS. This result was different from the previous larger-scaled study \[[@R30]\]. Our study scale might be insufficient to evaluate LMR.

Both NLR and LMR are still controversial as prognostic factors for PFS of EGFR-TKI treatment. In our survival comparisons, PFSs of patients with NLR ≥ 2.11 and LMR \< 5.09 were significantly shorter than those of patients with NLR \< 2.11 and LMR ≥ 5.09, respectively. However, our multivariate analyses did not detect NLR and LMR as independent prognostic factors for PFS. As an independent prognostic factor for shorter PFS, NLR ≥ 3.5 \[[@R27], [@R28]\] and NLR ≥ 5 \[[@R26]\] were demonstrated by previous studies. However, a Korean study failed to demonstrate NLR ≥ 3 as a significant prognostic factor \[[@R29]\]. On the other hand, a Taiwan study found that high baseline LMR was an independent prognostic factor for PFS of first-line TKIs \[[@R30]\], which was contrary to ours. Between the Taiwan and our studies, there seemed to be some differences in age (65.2 ± 12.4 vs. 70.3 ± 10.3 years) and proportion of TKI in the first-line setting (100% vs. 68.4%). Furthermore, significant prognostic factors detected by multivariate analyses for PFS were different. Our study found ECOG PS (0 - 1 vs. 2 - 4) and TKI line setting (first vs. second or later line), while the Taiwan study detected LMR, the 1-month-to-basline ratio of LMR, EGFR mutation (common vs. uncommon) and distant metastases (0 - 2 vs. \> 2). Thus, there is no established view on these two biomarkers as prognostic factors for PFS.

Our study included some limitations. First, we are afraid that our study was too small to find these two biomarkers as significant factors. Especially, our study underestimated LMR as a prognostic factor for OS. Second, our study might include case bias because of a single-centered and retrospective study. Multi-centered, prospective and larger-sized studies are ideal for such a specific cancer population.

Conclusions {#s4a}
-----------

This study demonstrated that elevated NLR is an independent prognostic factor for poor survival of patients with EGFR mutant NSCLC. NLR is a useful and simple biomarker for these patients, while LMR requires further studies as a significant biomarker.

We are grateful to Sung-Ho Kim, Yoshimi Noda, Yuki Nakatani, Kanako Nishimatsu, Shouko Ikuta, Saori Ikebe and Hideyasu Okada at the Department of Respiratory Medicine, Osaka Police Hospital for their detailed medical records, diagnosis, treatment and care of their patients.

Conflict of Interest {#s4a1a}
====================

The authors declare that they have no conflict of interest.

Grant Support {#s4a1b}
=============

None.
